
MOLN Stock Forecast & Price Target
MOLN Analyst Ratings
Bulls say
Molecular Partners is well-positioned in the competitive landscape of proprietary molecular therapeutics, as evidenced by Zai Lab's agreements for DLL3-targeted ADC development with Amgen and Boehringer Ingelheim, and Daiichi Sankyo's licensing of MP0423. Preclinical data for MP0712 and MP0726 support its potential in the rapidly growing field of radioligand therapy, and we expect strong revenue generation (approximately $298M) from MP0712 in treating SCLC and NETs. Additionally, ongoing efforts to improve operational efficiency and profitability, such as AbbVie's licensing of alveltamig, are a positive indicator for the company's long-term success in the market.
Bears say
Molecular Partners is currently collaborating with Orano Med on ten potential programs, and even though they have had some initial success in pre-clinical and clinical development, the company has never been profitable and there is no guarantee that it will ever become profitable. Additionally, the biopharma industry is inherently volatile, and the company may face significant regulatory challenges with their treatments.
This aggregate rating is based on analysts' research of Molecular Partners AG and is not a guaranteed prediction by Public.com or investment advice.
MOLN Analyst Forecast & Price Prediction
Start investing in MOLN
Order type
Buy in
Order amount
Est. shares
0 shares